|
Name |
(3S,11R,12S)-5-(furan-3-yl)-12-hydroxy-3,11-dimethyl-6,14-dioxatetracyclo[10.2.2.02,11.03,8]hexadec-15-ene-7,13-dione
|
| Molecular Formula | C20H22O6 | |
| IUPAC Name* |
(3S,11R,12S)-5-(furan-3-yl)-12-hydroxy-3,11-dimethyl-6,14-dioxatetracyclo[10.2.2.02,11.03,8]hexadec-15-ene-7,13-dione
|
|
| SMILES |
C[C@@]12CCC3C(=O)OC(C[C@]3(C1C4C=C[C@]2(C(=O)O4)O)C)C5=COC=C5
|
|
| InChI |
InChI=1S/C20H22O6/c1-18-9-14(11-5-8-24-10-11)25-16(21)12(18)3-6-19(2)15(18)13-4-7-20(19,23)17(22)26-13/h4-5,7-8,10,12-15,23H,3,6,9H2,1-2H3/t12?,13?,14?,15?,18-,19-,20-/m1/s1
|
|
| InChIKey |
AALLCALQGXXWNA-UTOPOAIZSA-N
|
|
| Synonyms |
Columbin; ISOCOLUMBIN; 471-54-5; 546-97-4
|
|
| CAS | NA | |
| PubChem CID | 146158961 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 358.4 | ALogp: | 2.2 |
| HBD: | 1 | HBA: | 6 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 86.0 | Aromatic Rings: | 6 |
| Heavy Atoms: | 26 | QED Weighted: | 0.612 |
| Caco-2 Permeability: | -5.28 | MDCK Permeability: | 0.00001700 |
| Pgp-inhibitor: | 0.308 | Pgp-substrate: | 0.003 |
| Human Intestinal Absorption (HIA): | 0.019 | 20% Bioavailability (F20%): | 0.063 |
| 30% Bioavailability (F30%): | 0.072 |
| Blood-Brain-Barrier Penetration (BBB): | 0.92 | Plasma Protein Binding (PPB): | 88.04% |
| Volume Distribution (VD): | 2.144 | Fu: | 18.85% |
| CYP1A2-inhibitor: | 0.048 | CYP1A2-substrate: | 0.644 |
| CYP2C19-inhibitor: | 0.548 | CYP2C19-substrate: | 0.562 |
| CYP2C9-inhibitor: | 0.379 | CYP2C9-substrate: | 0.037 |
| CYP2D6-inhibitor: | 0.021 | CYP2D6-substrate: | 0.144 |
| CYP3A4-inhibitor: | 0.892 | CYP3A4-substrate: | 0.455 |
| Clearance (CL): | 9.096 | Half-life (T1/2): | 0.059 |
| hERG Blockers: | 0.027 | Human Hepatotoxicity (H-HT): | 0.24 |
| Drug-inuced Liver Injury (DILI): | 0.194 | AMES Toxicity: | 0.014 |
| Rat Oral Acute Toxicity: | 0.965 | Maximum Recommended Daily Dose: | 0.894 |
| Skin Sensitization: | 0.073 | Carcinogencity: | 0.723 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.017 |
| Respiratory Toxicity: | 0.939 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003282 | ![]() |
0.328 | D0G6AB | ![]() |
0.262 | ||
| ENC003107 | ![]() |
0.323 | D0D1SG | ![]() |
0.252 | ||
| ENC002056 | ![]() |
0.321 | D0IL7L | ![]() |
0.252 | ||
| ENC005049 | ![]() |
0.314 | D0P0HT | ![]() |
0.250 | ||
| ENC002850 | ![]() |
0.310 | D0I5DS | ![]() |
0.248 | ||
| ENC002903 | ![]() |
0.297 | D0V9DZ | ![]() |
0.248 | ||
| ENC002851 | ![]() |
0.294 | D08PIQ | ![]() |
0.248 | ||
| ENC003323 | ![]() |
0.279 | D0K7LU | ![]() |
0.245 | ||
| ENC005203 | ![]() |
0.277 | D06AEO | ![]() |
0.241 | ||
| ENC001928 | ![]() |
0.277 | D0C7JF | ![]() |
0.239 | ||